Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

UFS makes history as a second researcher – Prof Melanie Walker – receives NRF A-rating
2014-12-03

Prof Melanie Walker
Photo: Sonia Small

Prof Melanie Walker, Senior Research Professor at the University of the Free State’s (UFS) Centre for Research on Higher Education and Development (CRHED) has received an A1 rating from the National Research Foundation (NRF). This rating acknowledges Prof Walker as a leading international researcher – her work unequivocally recognised by peers world-wide for its high quality and wide impact.

This is the first time in our institution’s history that two A-ratings are awarded simultaneously. Prof Maxim Finkelstein from the Department of Mathematical Statistics also recently received an A2-rating in Probability and Statistics from the NRF.

“Achieving this outstanding rating,” Prof Walker says, “is not just an individual achievement. I have had tremendous personal support and rich intellectual collaborations from wonderful colleagues on the way. The award also recognises the Rector’s project to build a dynamic research culture at UFS.”

Prof Walker has been researching and writing about issues in education and higher education for over 20 years. In particular she is interested in opportunities into, through and beyond education across dimensions of dis/advantage, and how higher education contributes to building a decent society by removing inequalities in its own policies and processes.

Through her focus on capacity building – around the common theme of higher education, human development and social justice – Prof Walker is developing a dynamic cohort of new-generation scholars. Her research group of graduate students and post-doctoral fellows is drawn from countries not only in Africa, but as far afield as Finland, India and Vietnam.

Her networks attract international scholars to the UFS, who contribute to research projects, engage graduate students, and add a considerable contribution to research at our university.

In addition, Prof Walker fulfils a host of roles, which includes:

• Tier One National Research Foundation (NRF) Chair in Higher Education and Human Development.
• Vice-President of the international Human Development and Capability Association (HDCA).
• Fellow of the Academy of Science of South Africa (ASSAf).
• Honorary professor, University of Nottingham, UK.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept